127 related articles for article (PubMed ID: 16037294)
1. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors.
Schupp N; Schinzel R; Heidland A; Stopper H
Ann N Y Acad Sci; 2005 Jun; 1043():685-95. PubMed ID: 16037294
[TBL] [Abstract][Full Text] [Related]
2. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products: a possible link to angiotensin in an animal model.
Bohlender J; Franke S; Sommer M; Stein G
Ann N Y Acad Sci; 2005 Jun; 1043():681-4. PubMed ID: 16037293
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis.
Chan YC; Leung PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):10-8. PubMed ID: 17616560
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging.
Schupp N; Schmid U; Rutkowski P; Lakner U; Kanase N; Heidland A; Stopper H
Am J Physiol Renal Physiol; 2007 May; 292(5):F1427-34. PubMed ID: 17229674
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone induces oxidative stress, oxidative DNA damage and NF-κB-activation in kidney tubule cells.
Queisser N; Oteiza PI; Stopper H; Oli RG; Schupp N
Mol Carcinog; 2011 Feb; 50(2):123-35. PubMed ID: 21229609
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.
Morcos M; Schlotterer A; Sayed AA; Kukudov G; Oikomonou D; Ibrahim Y; Pfisterer F; Schneider J; Bozorgmehr F; Rudofsky G; Schwenger V; Kientsch-Engels R; Hamann A; Zeier M; Dugi K; Yard B; Humpert PM; van der Woude F; Nawroth PP; Bierhaus A
Horm Metab Res; 2008 Nov; 40(11):752-9. PubMed ID: 18711692
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
[TBL] [Abstract][Full Text] [Related]
9. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction.
Vaziri ND; Bai Y; Ni Z; Quiroz Y; Pandian R; Rodriguez-Iturbe B
J Pharmacol Exp Ther; 2007 Oct; 323(1):85-93. PubMed ID: 17636006
[TBL] [Abstract][Full Text] [Related]
10. Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions.
Kowluru RA
Life Sci; 2005 Jan; 76(9):1051-60. PubMed ID: 15607333
[TBL] [Abstract][Full Text] [Related]
11. Interactions between renin angiotensin system and advanced glycation in the kidney.
Thomas MC; Tikellis C; Burns WM; Bialkowski K; Cao Z; Coughlan MT; Jandeleit-Dahm K; Cooper ME; Forbes JM
J Am Soc Nephrol; 2005 Oct; 16(10):2976-84. PubMed ID: 16107577
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells.
Zhou YJ; Yang HW; Wang XG; Zhang H
Life Sci; 2009 Nov; 85(19-20):670-7. PubMed ID: 19778541
[TBL] [Abstract][Full Text] [Related]
13. New approaches for the treatment of genomic damage in end-stage renal disease.
Schupp N; Schmid U; Heidland A; Stopper H
J Ren Nutr; 2008 Jan; 18(1):127-33. PubMed ID: 18089459
[TBL] [Abstract][Full Text] [Related]
14. AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment.
Schupp N; Rutkowski P; Sebeková K; Klassen A; Bahner U; Grupp C; Heidland A; Stopper H
Kidney Blood Press Res; 2011; 34(3):167-72. PubMed ID: 21474964
[TBL] [Abstract][Full Text] [Related]
15. Free radicals, metals and antioxidants in oxidative stress-induced cancer.
Valko M; Rhodes CJ; Moncol J; Izakovic M; Mazur M
Chem Biol Interact; 2006 Mar; 160(1):1-40. PubMed ID: 16430879
[TBL] [Abstract][Full Text] [Related]
16. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
Wolf G
Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
[TBL] [Abstract][Full Text] [Related]
17. Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute?
Sebeková K; Wagner Z; Schupp N; Boor P
Kidney Blood Press Res; 2007; 30(1):56-66. PubMed ID: 17261927
[TBL] [Abstract][Full Text] [Related]
18. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and advanced glycation in diabetic nephropathy.
Coughlan MT; Mibus AL; Forbes JM
Ann N Y Acad Sci; 2008 Apr; 1126():190-3. PubMed ID: 18448815
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.
Portero-Otín M; Pamplona R; Boada J; Jové M; Gonzalo H; Buleon M; Linz W; Schäfer S; Tack I; Girolami JP
Biochem Biophys Res Commun; 2008 Apr; 368(3):528-35. PubMed ID: 18243127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
